Floatz logo

PEGIPANERMIN

Mental Disorders

Inmune Bio, Inc.protein_peptidePhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Mental Disorders cohort.

Asset / SponsorPhaseRating
Opc-34712
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3BBB
Provigil
Emory University
Phase 4BB
Naltrexone
State University of New York - Upstate Medical University
Phase 4BB
Galantamine Hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3BB
Gardasil 9 Vaccine
Eunice Dube
Phase 4BB

View all 37 →

Same molecule, other indications

PEGIPANERMIN is also rated in:

Alzheimer diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
dementiaDormant
CCC
Indicative ·
48 / 100
View asset →
brain disorderDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →